Combining Pembrolizumab with Double Platinum Chemotherapy for Lung Cancer
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Hunan Province Tumor Hospital · NCT04324151
This study is testing if combining a drug called Pembrolizumab with double platinum chemotherapy can help people with advanced lung cancer that can potentially be surgically removed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital (other) |
| Drugs / interventions | Chemotherapy, Pembrolizumab |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT04324151 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of combining Pembrolizumab with double platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer (NSCLC) that does not have driver gene mutations. The trial focuses on treatment-naive patients who have been diagnosed with advanced non-squamous NSCLC and are deemed potentially resectable by a multidisciplinary team. The study aims to gather data on how this combination therapy impacts patient outcomes and overall treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced non-squamous non-small cell lung cancer that is potentially resectable and treatment-naive.
Not a fit: Patients who are pregnant, breastfeeding, or have contraindications to chemotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with advanced non-small cell lung cancer.
How similar studies have performed: While this approach is being explored, similar studies combining immunotherapy with chemotherapy have shown promise in other cancer types, but this specific combination in NSCLC is still being evaluated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Potentially Resectable NSCLC * Treatment Plan is Crizotinb or Standard Chemotherapy Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Where this trial is running
Changsha, Hunan
- Yongchang Zhang — Changsha, Hunan, China (RECRUITING)
Study contacts
- Principal investigator: Yongchang Zhang — Hunan Cancer Hospital
- Study coordinator: Yongchang Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non Small Cell Lung Cancer